(Q34392227)

1 August 2017

1 reference

title

Hypothalamic hormones and cancer (English)

1 reference

1 August 2017

1

Schally AV

1 reference

1 August 2017

2

Comaru-Schally AM

1 reference

1 August 2017

Nagy A

3

1 reference

1 August 2017

Kovacs M

4

1 reference

1 August 2017

Szepeshazi K

5

1 reference

1 August 2017

Plonowski A

6

1 reference

1 August 2017

Varga JL

7

1 reference

1 August 2017

Halmos G

8

1 reference

1 August 2017

publication date

1 October 2001

1 reference

Frontiers in Neuroendocrinology

1 August 2017

published in

1 reference

1 August 2017

volume

22

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

248-291

1 reference

Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II

1 August 2017

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Hypothalamic Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH)-Regulating Hormone: Structure, Physiology, and Clinical Studies**The work described here has been supported by research grants from the Veterans Administration, United State

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Effects of LHRH-analogues on mitogenic signal transduction in cancer cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Molecular pharmacology of somatostatin receptor subtypes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Isolation and properties of the FSH and LH-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Aspects of hypothalamic regulation of the pituitary gland

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Gonadotropin-Releasing Hormone Receptors: Characterization, Physiological Regulation, and Relationship to Reproductive Function

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Multiple actions of somatostatin in neoplastic disease

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Peptide analogs in the therapy of prostate cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix).

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Somatostatin analogue scintigraphy in carcinoid tumours

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Endocrine treatment of breast cancer in women

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Mechanisms of antineoplastic action of somatostatin analogs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1006/FRNE.2001.0217

Identifiers

DOI

10.1006/FRNE.2001.0217

1 reference

1 August 2017

1 reference